Video
Author(s):
Srdan Verstovsek, MD, PhD, discusses ongoing research in myelofibrosis-related anemia.
This is a modal window.
Beginning of dialog window. Escape will cancel and close the window.
End of dialog window.
This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.
Srdan Verstovsek, MD, PhD, United Energy Resources, Inc. Professor of Medicine, director, Hanns A. Pielenz Clinical Research Center for Myeloproliferative Neoplasms, chief, Section for Myeloproliferative Neoplasms, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses ongoing research in myelofibrosis-related anemia.
Although JAK inhibitors are effective treatments for reducing splenomegaly and controlling symptoms in myelofibrosis, anemia remains a challenge for this patient population, Verstovsek explains. As such, novel therapies are in development with the goal of treating anemia in myelofibrosis.
Luspatercept-aamt (Reblozyl) is being evaluated in the ongoing phase 3 INDEPENDENCE trial (NCT04717414) vs placebo in patients with myeloproliferative neoplasm–associated myelofibrosis who are receiving JAK inhibitor therapy and requiring red blood transfusions. Combining luspatercept with JAK inhibitors, such as ruxolitinib (Jakafi), could improve anemia while decreasing splenomegaly and controlling symptoms, Verstovsek says.
Notably, anemia remains the leading cause of ruxolitinib discontinuation in myelofibrosis, so patients requiring treatment in the second-line setting often have a much higher degree of anemia or thrombocytopenia compared with patients in the frontline setting, Verstovsek says. In the second-line setting, momelotinib is being evaluated in comparison with danazol for symptomatic and anemic patients with myelofibrosis previously treated with a JAK inhibitor in the phase 3 MOMENTUM trial (NCT04173494), Verstovsek concludes.
Observation Is a Reasonable Alternative to Adjuvant PD-1 Blockade in Stage IIB/IIIC Melanoma
Dr Oluwole on CRS and Neurotoxicity Beyond 2 Weeks After Axi-Cel Infusion in R/R LBCL
Dr Garfall on Ide-Cel and Lenalidomide Maintenance in Myeloma After Suboptimal ASCT Response
Piflufolastat F18 Imaging Is Associated With High Clinician Confidence in Prostate Cancer Management
Mirdametinib Provides Long-Awaited Treatment Option in NF1-Associated PN
Biomarker-Driven Research Accelerates Drug Discovery and Precision Medicine Approaches in Sarcoma
Neoadjuvant Chemo and Concurrent Chemoradiation Is a Safe, Effective Bladder-Sparing Approach in Nonmetastatic MIBC
Some Patients With Kidney Cancer Can Stop Combination Treatment After Two Years, Fox Chase Cancer Center Study Finds
2 Commerce Drive
Cranbury, NJ 08512